1. Home
  2.  |  
  3. News Capsule |  

Kallam Anji Reddy, Dr Reddy's Laboratories Founder Died At 72

Mar 16, 2013 12:58 IST

Kallam Anji Reddy, the main behind Dr Reddy's Laboratories Ltd (DRL), the second-largest drugmaker of India died on 15 March 2013 at Hyderabad’s Apollo Hospital. Anji Reddy was the founder and chairman of DRL. He was aged 72 years. He died because of liver cancer. He is survived by his wife, daughter and son.

About Kallam Anji Reddy

• Anji Reddy was a chemical engineer.
• He served as the member on Prime Minister's Council on Trade & Industry.
• Anji Reddy was honoured with Padma Bhushan, the highest Civilian Award in India, in April 2011. He was awarded for distinguished service in Trade and Industry field.
• He also founded Neo-natal Intensive Care and Emergencies called NICE Foundation, which is the only institute for new-borns in Asia.
• In 1998, he also established Naandi Foundation which provided safe drinking water in rural areas. This foundation also provides the midday meals to 1.3 million children as well as farmers.

About Dr Reddy's Laboratories Ltd (DRL)

Dr Reddy's Laboratories is the second-largest pharmaceutical company of India, in terms of market capitalization with 31000 crore Rupees.

It was also the first pharmaceutical company of India that was listed on the New York Stock Exchange in 2001.

Is this article important for exams ? Yes9 People Agreed
Read more Current Affairs on: Kallam Anji Reddy , Dr Reddy's Laboratories

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK